extract from the cohen report

"With Phase 3 scheduled to begin in 2005, we
believe the NDA filing with the FDA will occur in
2006 with approval in 2007.

Pharmaceutical firms interested in Metabolic’s obesity therapy may desire additional data from the Phase 2 trial, which should be complete towards the end of calendar year 2004.

Due to the implications such a drug may have on
reducing healthcare costs, the FDA may ‘fast track’
the approval process".
________________________________

Comment:
That last paragraph is interesting.

Gerry